A Novel CTC-Detecting Technique Using TelomeScan and Its Clinical Applications

Similar documents
Challenges for use of CTCs as a Diagnostic. Farideh Z. Bischoff, Ph.D. Interim CSO Sr. Director, Translational Clinical Development Biocept, Inc.

CTC in clinical studies: Latest reports on GI cancers

La biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro

Nature Methods: doi: /nmeth Supplementary Figure 1

WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE CANCER PATIENTS

Youngnam Cho. National Cancer Center Biomarker Branch

Circulating Tumor Cells in non- Metastatic Triple Negative Breast Cancer

Liquid Biopsy: Implications for Cancer Staging & Therapy

Cover Letter. Reviewer 1:

High Sensitivity Immunomagnetic CTC Isolation as Compared to Alternative Isolation Methods

WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE1 CANCER PATIENTS

A simple biological imaging system for detecting viable human circulating tumor cells

Circulating tumor cells as a prognostic factor in patients with small cell lung cancer

Circulating Stromal Cells in Immunotherapy Utilizing a Total Blood Based Biopsy

The CellCollector TM technology

Incorporating pharmacodynamic, response and patient selection biomarkers. Paul Elvin PhD Chief Translational Science Officer Aptus Clinical

The Presence and Persistence of Resistant and Stem Cell- Like Tumor Cells as a Major Problem in Ovarian Cancer

Qué hemos aprendido hasta hoy? What have we learned so far?

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.

Detection of Circulating Tumor Cells Harboring a Unique ALK-Rearrangement in ALK- Positive Non-Small-Cell Lung Cancer.

CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS

The Avatar System TM Yields Biologically Relevant Results

Circulating Tumor Cells (CTC) Technologies

Fluorescent virus-guided capturing system of human colorectal circulating tumor. cells for non-invasive companion diagnostics

WHEN STARTING A NEW LINE OF THERAPY FOR YOUR METASTATIC BREAST, COLORECTAL, AND PROSTATE 1 CANCER PATIENTS

Neoplasia 18 lecture 6. Dr Heyam Awad MD, FRCPath

Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego

VIII Curso Internacional del PIRRECV. Some molecular mechanisms of cancer

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

Circulating Tumor Cell Kit (Epithelial)

Integrated platform for liquid biopsy-based personalized cancer medicine

The Role of CTCs as Tumor Biomarkers

number Done by Corrected by Doctor Maha Shomaf

Detection of the Circulating Tumor Cells in Cancer Patients

AdnaNews. News from the meeting on Advances in Circulating Tumor Cells (ACTC), Reythymnon, Crete, Greece October 8-11, 2014.

Page: 1 of 10. Detection of Circulating Tumor Cells in the Management of Patients with Cancer

Urinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring. Summit August 19,2015

Detecting Oncogenic Mutations in Whole Blood

Cancer Biology Course. Invasion and Metastasis

Cell Polarity and Cancer

In most industrialized countries, primary lung cancer is. Circulating Tumor Cells in Pulmonary Venous Blood of Primary Lung Cancer Patients

Cancer genetics

Table S1: Analysis of Notch gene rearrangements in triple negative breast cancer subtypes

Liquid Biopsy. Jesus Garcia-Foncillas MD PhD. Director

CTC molecular characterization: Are we ready to move forward with clinical testing?

Supplemental Information. High-Throughput Microfluidic Labyrinth for the. Label-free Isolation of Circulating Tumor Cells

1/23/2017. Alarice Lowe, MD Assistant Professor of Pathology Director, Circulating Tumor Cell Lab Brigham and Women s Hospital Harvard Medical School

Big data vs. the individual liver from a regulatory perspective

R.G.C.C.-RESEARCH GENETIC CANCER CENTRE. Florina, 28 / 12 / 2006 Dear Dr. Gilbard and Dr. Hammon, LIPOMAS, UNDIAGNOSED PAIN, FAMILY HISTORY OR CANCER

Nature Medicine: doi: /nm.4322

Lecture 1: Carcinogenesis

Lecture 1: Carcinogenesis

Review. Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis capable malignancy.

SUPPLEMENTARY INFORMATION

Lukas Bubendorf Pathologie. Liquid biopsies

Review Article Significance of Circulating Tumor Cells Detected by thecellsearchsysteminpatientswithmetastaticbreast Colorectal and Prostate Cancer

Circulating tumor cells/dna/etc for Radiation Oncologists

Pros and cons of liquid biopsy: Ready to replace tissue?

When starting a new line of therapy for your metastatic breast, colorectal, and prostate 1 cancer patients

oncogenes-and- tumour-suppressor-genes)

Transformation of Normal HMECs (Human Mammary Epithelial Cells) into Metastatic Breast Cancer Cells: Introduction - The Broad Picture:

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Interactions between cancer stem cells and their niche govern metastatic colonization

Accelerate Your Research with Conversant Bio

Page: 1 of 10. Detection of Circulating Tumor Cells in the Management of Patients with Cancer

Disclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath

Corporate Medical Policy

Supplementary Tables. Supplementary Figures

METACELL. PERSONALIZED CANCER THERAPY USING CIRCULATING TUMOR CELLS (CTCs) METACELL LIQUID BIOPSY

Early dissemination in prostate cancer

Integrative Biology REVIEW ARTICLE. Liquid biopsy on chip: a paradigm shift towards the understanding of cancer metastasis. 1.

TMA-VARESE COHORT-1 TMA-BERN COHORT-2

Protocol for A-549 VIM RFP (ATCC CCL-185EMT) TGFβ1 EMT Induction and Drug Screening

CANCER. Inherited Cancer Syndromes. Affects 25% of US population. Kills 19% of US population (2nd largest killer after heart disease)

Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures

Circulating tumor cells

Tumor microenvironment Interactions and Lung Cancer Invasiveness. Pulmonary Grand Rounds Philippe Montgrain, M.D.

MicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Cell-free tumor DNA for cancer monitoring

Deregulation of signal transduction and cell cycle in Cancer

Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS

LIQUID BIOPSY

How close are we to standardised extended RAS gene mutation testing? The UK NEQAS experience

Learn your genetic risk for the most common hereditary cancers.

Development of Carcinoma Pathways

Biochemistry of Cancer and Tumor Markers

Agenda. What is a Liquid Biopsy? Biocept technology. Concordance With Tissue. Clinical Applications. Billing and Reimbursement.

The OncoBEAM Platform: The Use of a High Sensitive Technology for Liquid Biopsies in Clinical Practice

Prospective Clinical Study of Circulating Tumor Cells For Colorectal Cancer Screening

The Pathology of Neoplasia Part II

Liquid biopsy: the experience of real life case studies

Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer

Detection of Circulating Tumor Cells Harboring a Unique ALK Rearrangement in ALK-Positive Non Small-Cell Lung Cancer

of TERT, MLL4, CCNE1, SENP5, and ROCK1 on tumor development were discussed.

Supplementary Online Content

Nature Immunology: doi: /ni Supplementary Figure 1. Huwe1 has high expression in HSCs and is necessary for quiescence.

In vitro scratch assay: method for analysis of cell migration in vitro labeled fluorodeoxyglucose (FDG)

Transcription:

A Novel CTC-Detecting Technique Using TelomeScan and Its Clinical Applications Yasuo Urata CEO and President Oncolys BioPharma Inc. February 16, 2013

Telomere Length is a Limiting Factor for Cell Replication Cell senescence Telomere shortening Shay JW and Wright WE, Nat Rev Mol Cell Biol. 1:72-6. 2

Telomerase Activity in Cancer Cells and Biopsies Cell lines - Telomerase (+) in 98/100 immortal cell lines - Telomerase (-) in 22/22 mortal cell lines Biopsies - Telomerase (+) in 90/101 human tumors - Telomerase (-) in 50/50 human normal tissues Telomerase is an universal marker in all types of human cancer Kim NW, et al. Science. (1994) 3

Telomerase and htert Normal Cancer htert GAPDH Structure of Telomerase Complex Human telomerase is a complex consisting of template RNA and enzyme subunits including htert, human telomerase reverse transcriptase. Distribution of htert htert is expressing in cancer and some normal stem cells but not in normal somatic cells. 4

Structure of TelomeScan Telomerase Green Fluorescent Protein (GFP) TelomeScan is genetically engineered GFP gene-carrying adenovirus of which viral replication is under the control of htert promoter. 5

Fluorescent Detection of Cancer Cells by TelomeScan Normal cells (Telomerase negative) No virus replication and GFP production Virus infection Fluorescence TelomeScan GFP Cancer cells (Telomerase positive) Virus replication and GFP production 6

Cancer Specific GFP Expression by TelomeScan SW620; Human Colon Cancer Cells NHLF; Normal Fibroblast 2 h 12 h 24 h 48 h 72 h 24 h 72 h 120 h HT29; Human Colon Cancer Cells 2 h 12 h 24 h 48 h 72 h Kishimoto et al., Nat Med. 12:1213-1219. (2006) 7

Tumor Metastasis and Circulating Tumor Cells (CTC) Chaffer CL and Weinberg RA. Science, 331: 1559-1564, 2011. 8

Veridex CellSearch System for CTC detection CTC Ferrofluid Anti-EpCAM WBC Anti-CD45-APC Nucleus DAPI EpCAM AB CK Nucleus DAPI CD45 AB Cytokeratin Anti-CK 8,18,19-PE CTC is separated by anti-epcam WBC is removed by anti-cd45 The FDA-approved Veridex LLC CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells (CTC) of epithelia origin (CD45-, EpCAM+, and cytokeratins8, 18+, and/or 19+) in peripheral blood samples. 9

Correlation of Prognosis and CTC number detected by CellSearch The assay predicts progression-free survival (PFS) and overall survival (OS) in patients treated for metastatic breast, colon and prostate cancer. A CTC count of 5 cells / 7.5mL blood or greater as determined by the assay is predictive of shorter PFS and OS for patients with metastatic breast and/or prostate cancer. A CTC count of 5 cells / 7.5mL blood or greater is predictive of shorter PFS and OS for patients with metastatic colon cancer. 10 10

Restricted Sensitivity of CellSearch CTC detection rate of CellSearch TM system in various metastatic cancer patients Prostate cancer Ovarian cancer Breast cancer Stomach cancer Colorectal cancer Lung cancer Pancreatic cancer Healthy person benign disease Measured range of CTC number (mean ± S.D.); 0~23,618 cells/7.5ml (60 ± 693 cells) Sample ratio that had more than 2 cells/7.5ml (Ratio); Mean 36% Sample ratio that had more than 5 cells/7.5ml (Ratio); Mean 24% 11

Sensitivity of TelomeScan in NSCLC Cell Lines - Quantitative measurement of GFP expression by FACS - TelomeScan is feasible to detect CTCs in Lung Cancer Patients. 12

EpCAM and Cytokeratin Independent GFP expression in NSCLC Cell Lines Cytokeratin EpCAM TelomeScan (GFP) Cytokeratin EpCAM TelomeScan (GFP) HCC827 A549 EpCAM Negative H358 H460 H2170 H1299 H1975 H522 EpCAM/CK Negative H322 H661 H1650 H1703 13

High Sensitivity of TelomeScan Bright GFP Number of spiked cells 14

Clinical Application of TelomeScan for CTC detection and Analyses Sample Preparation TelomeScan kit CTC Enumeration T-CAS TelomeScan CTC Analysis System Super early detection of cancer Prognosis definition Evaluation of malignancy Lysis Infection Immunostaining 24 hrs Whole blood PBMC CTC isolation and its gene analysis T-GEN TelomeScan Genotyping System Gene analysis 15

Phenotyping of CTC using TelomeScan amd Immunostaining TelomeScan (GFP) CD45 Vimentin CTC detection Elimination of WBC Mesenchymal marker E-cadhelin(E-cad) Epithelial marker Bright Field H661 (NSLCS) EMT: Epithelial to Mesenchymal Transition Merge: GFP+CD45+Vim GFP+CD45+E-cad 16

Multiple Immunostaining Identifies Characteristics of NSCLC Cell Lines GFP CD45 Vimentin E-Cadherin Merged Bright field Epithelial H322 A549 Mesenchymal (EMT) H661 H1299 17

CTC Detection from NSCLC Patients TelomeScan PBMC Phenotyping marker Merge Bright field GFP CD45 Vim E-Cad Patient #1 CD14 Patient #2 18

CTC Detection from Patients of Various Types of Cancer Cancer type TelomeScan PBMC Phenotyping marker Merge Bright field Pancreas #1 GFP CD45 Pancreas #2 Vim E- Cad Colon CD14 Stomach Breast Bone 19

CTC Isolation Using Single-Cell Isolator Nano-litter scale manipulator equipped with Microscope X-Y-Z coordinates were calculated and cell collection is achieved automatically A cell is collected and drained out on PCR tube or glass slide Define a cell Capture Deposit Cells are collected on cap of PCR tube and directly processed for genetic mutational analysis 20

Genetic Mutational Analysis Test for EGFR in NSCLC Cell Lines Virus infection does not influence CTC mutational analysis EGFR mutation was detected from NSCLC cells Cells PC-9 (EGFR exon 19 deletion mutation) Virus MOI (MOI) Result 0 Exon 19del 10 Exon 19del 100 Exon 19del 1000 Exon 19del Cells # of cell Result H358 EGFR Wild Type HCC827 EGFR E746- A750del 1 PCR failed 3 WT 10 WT 1 PCR failed 3 E746-A750del 10 E746-A750del EGFR mutation was detected from 3 NSCLC cells with PBMC contaminant Cells # of cell Result 3 cancer cells + 12 PBMC E746-A750del detected HCC827 EGFR E746-A750del 3 cancer cells + 17 PBMC E746-A750del detected 3 cancer cells + 17 PBMC E746-A750del detected 21

Specification of TelomeScan Systems T-CAS (TelomeScan CTC Analysis System) is; 1. To detect telomerase-positive tumor cells 2. Not depends on EpCAM enrichment 3. Biological tool to detect only living CTC (L-CTC) T-GEN (TelomeScan Genotyping System) is; 1. To isolate a single L-CTC 2. To identify allele specific gene mutation of EGFR 3. Gene analysis system without biopsy 22